Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Primary biliary cholangitis in 2016

High-definition PBC: biology, models and therapeutic advances

Nature Reviews Gastroenterology & Hepatology volume 14, pages 76–78 (2017)Cite this article

Subjects

In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Converging themes in the pathophysiology and treatment of PBC.

References

  1. Hirschfield, G. M. & Gershwin, M. E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu. Rev. Pathol. 8, 303–330 (2013).

    Article  CAS  PubMed  Google Scholar 

  2. Trivedi, P. J., Corpechot, C., Pares, A. & Hirschfield, G. M. Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists. Hepatology 63, 644–659 (2016).

    Article  PubMed  Google Scholar 

  3. Bae, H. R. et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 64, 1189–1201 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cordell, H. J. et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat. Commun. 6, 8019 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chang, J. C. et al. Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes. Hepatology 64, 522–534 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hisamoto, S. et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. J. Autoimmun. 75, 150–160 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. Oo, Y. H. et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J. Hepatol. 57, 1044–1051 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Luo, J. et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl Med. 6, 247ra100 (2014).

    Article  PubMed  Google Scholar 

  9. Zhou, M. et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63, 914–929 (2016).

    Article  CAS  PubMed  Google Scholar 

  10. Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631–643 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

G.J.W. and G.M.H. are supported by the NIHR Birmingham Biomedical Research Unit. This report represents independent research partly supported by the NIHR Biomedical Research Unit Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Author information

Authors and Affiliations

  1. Centre for Liver Research, NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, Birmingham, B15 2TT, UK

    Gwilym J. Webb & Gideon M. Hirschfield

Authors
  1. Gwilym J. Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gideon M. Hirschfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gideon M. Hirschfield.

Ethics declarations

Competing interests

G.M.H. has been on primary biliary cholangitis advisory boards for GlaxoSmithKline, Intercept Pharmaceuticals and Novartis. G.M.H. has been a study investigator for CymaBay Therapeutics, Dr Falk Pharma, FF Pharma, GlaxoSmithKline, Gilead, Intercept Pharmaceuticals, NGM Bio, Novartis and Shire.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Webb, G., Hirschfield, G. High-definition PBC: biology, models and therapeutic advances. Nat Rev Gastroenterol Hepatol 14, 76–78 (2017). https://doi.org/10.1038/nrgastro.2016.201

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2016.201

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing